Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Expert Opinion on Emerging Drugs
|
October 25, 2021
Designing phase II clinical trials in Friedreich ataxia
Layne N Rodden, David R Lynch
Neurology. Genetics
|
May 27, 2022
Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia
Layne N Rodden, Christian Rummey, Yi Na Dong, et al.
Neurodegenerative Disease Management
|
June 29, 2022
Friedreich ataxia: clinical features and new developments
Medina Keita, Kellie McIntyre, Layne N Rodden, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 17, 2023
A Novel Metric for Predicting Severity of Disease Features in Friedreich's Ataxia
Layne N Rodden, Christian Rummey, Sudha Kessler, et al.
Frontiers in Neuroscience
|
December 13, 2021
Epigenetic Heterogeneity in Friedreich Ataxia Underlies Variable <i>FXN</i> Reactivation
Layne N Rodden, Kaitlyn M Gilliam, Christina Lam, et al.
Journal of Medical Genetics
|
January 12, 2023
<i>FXN</i> gene methylation determines carrier status in Friedreich ataxia
Christina Lam, Kaitlyn M Gilliam, Layne N Rodden, et al.
Annals of Clinical and Translational Neurology
|
June 19, 2023
Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxia
Layne N Rodden, Kellie McIntyre, Medina Keita, et al.
Frontiers in Neuroscience
|
April 11, 2022
Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia
Elizabeth Mercado-Ayón, Nathan Warren, Sarah Halawani, et al.
Scientific Reports
|
March 24, 2022
DNA methylation in Friedreich ataxia silences expression of frataxin isoform E
Layne N Rodden, Kaitlyn M Gilliam, Christina Lam, et al.
Human Molecular Genetics
|
January 12, 2021
Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia
Layne N Rodden, Yogesh K Chutake, Kaitlyn Gilliam, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Expert Opinion on Emerging Drugs
|
October 25, 2021
Designing phase II clinical trials in Friedreich ataxia
Layne N Rodden, David R Lynch
Neurology. Genetics
|
May 27, 2022
Clinical Evidence for Variegated Silencing in Patients With Friedreich Ataxia
Layne N Rodden, Christian Rummey, Yi Na Dong, et al.
Neurodegenerative Disease Management
|
June 29, 2022
Friedreich ataxia: clinical features and new developments
Medina Keita, Kellie McIntyre, Layne N Rodden, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 17, 2023
A Novel Metric for Predicting Severity of Disease Features in Friedreich's Ataxia
Layne N Rodden, Christian Rummey, Sudha Kessler, et al.
Frontiers in Neuroscience
|
December 13, 2021
Epigenetic Heterogeneity in Friedreich Ataxia Underlies Variable <i>FXN</i> Reactivation
Layne N Rodden, Kaitlyn M Gilliam, Christina Lam, et al.
Journal of Medical Genetics
|
January 12, 2023
<i>FXN</i> gene methylation determines carrier status in Friedreich ataxia
Christina Lam, Kaitlyn M Gilliam, Layne N Rodden, et al.
Annals of Clinical and Translational Neurology
|
June 19, 2023
Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxia
Layne N Rodden, Kellie McIntyre, Medina Keita, et al.
Frontiers in Neuroscience
|
April 11, 2022
Cerebellar Pathology in an Inducible Mouse Model of Friedreich Ataxia
Elizabeth Mercado-Ayón, Nathan Warren, Sarah Halawani, et al.
Scientific Reports
|
March 24, 2022
DNA methylation in Friedreich ataxia silences expression of frataxin isoform E
Layne N Rodden, Kaitlyn M Gilliam, Christina Lam, et al.
Human Molecular Genetics
|
January 12, 2021
Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia
Layne N Rodden, Yogesh K Chutake, Kaitlyn Gilliam, et al.
Page
of 2